Lead Pharma: Increasing Research Throughput with an ELN for Chemists and Biologists
Lead Pharma accelerates cancer and autoimmune disease drug discovery by integrating medicinal, structural, and computational chemistry with cell biology and omics technologies to develop first- and best-in-class small molecules, target protein production, and advanced assays and biomarkers.
Lead Pharma discovers and develops innovative therapeutics against cancer and autoimmune diseases.
The company has unparalleled expertise in the discovery and optimization of first- and best-in class small molecules for challenging drug targets. Lead Pharma’s drug discovery engine combines adept medicinal, structural and computational chemistry capability with complementary expertise in the fields of cell biology and omics technologies. The company’s innovative approach enables isolation, purification and manufacture of target proteins and the development of biochemical, cellular, and functional reporter assays as well as biomarkers.
Related
Data Management, Collaboration, and Workflow Optimisation: The Three Keys to Small Molecule Discovery Success
The article emphasizes that despite biologics' prominence, small molecule drug discovery is experiencing a renaissance driven by advances in screening, target exploration, and AI, but overcoming challenges like rising costs, data management, fragmented workflows, and CRO reliance requires success in three key areas: next-generation data management, enhanced cross-disciplinary research collaboration, and workflow optimization.
What is hit to lead stage in drug discovery?
The hit-to-lead (H2L) stage in drug discovery involves refining initial chemical hits with desired therapeutic effects by synthesizing, testing, and optimizing compounds through methods like structure-activity relationships, computational modeling, and high-throughput screening to identify and improve lead candidates with enhanced potency, specificity, and drug-like properties for further development.
How are small molecule drugs developed?
Small molecule drugs, typically organic compounds with low molecular weight that easily penetrate cells, are developed through interdisciplinary methods such as rational drug design, natural source isolation, phenotypic screening, and target-based drug discovery, and are widely used in medicinal applications including novel cancer therapies and RNA-targeting biochemical regulation.
Webinar: Three Key Considerations When Implementing AI in Drug Discovery
The webinar, led by Haydn Boehm, focuses on three key considerations—reasonable expectations, clean data, and collaboration—for successfully implementing AI in small molecule drug discovery amidst the current hype and ongoing preclinical development of AI-native candidates.
Principles and Processes of Early Drug Discovery
The early drug discovery process involves target identification and validation, hit discovery through confirming active compounds, assay development for testing effects, and employs various screening strategies such as high-throughput, virtual, phenotypic, and target-based screening to identify promising drug candidates.
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.